TickerKhojComparison · NSE · data 2026-11-03
Ind-Swift Laboratories Ltd. vs Shukra Pharmaceuticals Ltd.
In plain words
Size: Shukra Pharmaceuticals Ltd. is about 1.1 times the market value of Ind-Swift Laboratories Ltd..
Valuation (P/E): Shukra Pharmaceuticals Ltd. 103 vs Ind-Swift Laboratories Ltd. 35.6.
Return on equity: Shukra Pharmaceuticals Ltd. 28.9% vs Ind-Swift Laboratories Ltd. 3.4%.
Profit growth over 3 years: Shukra Pharmaceuticals Ltd. 71% a year vs Ind-Swift Laboratories Ltd. -3.2% a year.
Debt to equity: Shukra Pharmaceuticals Ltd. 0.06 vs Ind-Swift Laboratories Ltd. 0.01.
Differences in the numbers, not a recommendation of either stock.
Side by side
19 metrics shown
| INDSWFTLAB | SHUKRAPHAR | |
|---|---|---|
| Price | ₹343.75 | ₹79.85 |
| Market cap | ₹3,080 cr | ₹3,516 cr |
| P/E | 35.6 | 103 |
| P/B | 2 | — |
| ROE | 3.4% | 28.9% |
| ROCE | -0.2% | 31.3% |
| Debt / equity | 0.01 | 0.06 |
| Operating margin | 9.4% | 57.2% |
| Dividend yield | 0.00% | 0.01% |
| Sales growth, 3 years (yearly) | -19.6% | -1.2% |
| Profit growth, 3 years (yearly) | -3.2% | 71.0% |
| 1-year return | 234.7% | 89.9% |
| Revenue, last 12 months | ₹753 cr | ₹75 cr |
| Net profit, last 12 months | ₹84 cr | ₹34 cr |
| Latest quarter | Sept 2026 | — |
| Quarter net profit | ₹34 cr | — |
| Quarter profit vs a year earlier | +328.3% | — |
| Promoter holding | 42.93% | 51.15% |
| Health check | Average (5.7/10) | Strong (6.6/10) |
Common questions
Which has a higher P/E, Ind-Swift Laboratories Ltd. or Shukra Pharmaceuticals Ltd.?
Shukra Pharmaceuticals Ltd. trades at the higher P/E (103 against 35.6). A higher P/E means the market pays more for each rupee of past earnings; on its own it does not say which is better.
Which earns a higher return on equity?
Shukra Pharmaceuticals Ltd. (28.9% against 3.4%).
Which carries more debt?
Shukra Pharmaceuticals Ltd. has the higher debt-to-equity ratio (0.06 against 0.01).